Bristol Myers Squibb is integrating artificial intelligence across its research and development pipeline to accelerate medicine delivery. SVP for R&D Matteo diTommaso detailed the company's transition from a data strategy to active AI deployment in a Forbes feature.
The company utilizes a learning by doing approach to encourage secure workforce adoption of AI tools. A central development is the Development Operations Workbench, an AI-powered platform designed to streamline clinical trial operations.
The platform integrates data from multiple systems to provide AI-generated insights. These insights allow teams to identify and address potential risks early, preventing delays in clinical trials.